Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target.

ABSTRACT: The vascular obstructive thrombus is composed of a mesh of fibrin fibers with blood cells trapped in these networks. Enhanced fibrin clot formation and/or suppression of fibrinolysis are associated with an increased risk of vascular occlusive events. Inhibitors of coagulation factors and activators of plasminogen have been clinically used to limit fibrin network formation and enhance lysis. While these agents are effective at reducing vascular occlusion, they carry a significant risk of bleeding complications. Fibrin clot lysis, essential for normal hemostasis, is controlled by several factors including the incorporation of antifibrinolytic proteins into the clot. Plasmin inhibitor (PI), a key antifibrinolytic protein, is cross-linked into fibrin networks with higher concentrations of PI d

SUBMITTER: Alsayejh B 

PROVIDER: S-EPMC9674435 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature